5/23
02:50 pm
kzia
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement [Yahoo! Finance]
5/23
02:41 pm
kzia
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
Low
Report
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
5/2
05:19 am
kzia
Kazia concludes first stage of Phase I advanced cancer treatment trial [Yahoo! Finance]
High
Report
Kazia concludes first stage of Phase I advanced cancer treatment trial [Yahoo! Finance]
5/1
09:02 am
kzia
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS [Yahoo! Finance]
Medium
Report
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS [Yahoo! Finance]
5/1
08:45 am
kzia
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
High
Report
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
3/21
09:10 am
kzia
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]
High
Report
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]
3/21
08:52 am
kzia
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Medium
Report
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases